Douglas K. Graham
Affiliations: | 2003-2015 | Molecular Biology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
2015- | Pediatrics | Emory University, Atlanta, GA |
Area:
Molecular Biology, Cancer Biology, Pediatric Leukemia, Receptor Tyrosine KinaseGoogle:
"Douglas Graham"Children
Sign in to add traineeSufit, A | grad student | University of Colorado, Denver | |
Christopher Cummings | grad student | University of Colorado, Denver | |
Kristen Jacobsen | grad student | University of Colorado, Denver | |
Justine C. Migdall-Wilson | grad student | 2012 | University of Colorado, Denver |
Jennifer Schlegel | grad student | 2012 | University of Colorado, Denver |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
DeRyckere D, Huelse JM, Earp HS, et al. (2023) TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nature Reviews. Clinical Oncology |
Kelvin JM, Chimenti ML, Zhang DY, et al. (2023) Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia. Journal of Controlled Release : Official Journal of the Controlled Release Society |
Summers RJ, Jain J, Vasileiadi E, et al. (2022) Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14 |
Yan D, Huelse JM, Kireev D, et al. (2022) MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. The Journal of Clinical Investigation |
Yan D, Earp HS, DeRyckere D, et al. (2021) Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. Cancers. 13 |
Zheng H, Zhao J, Li B, et al. (2021) UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry. 220: 113534 |
Huelse JM, Fridlyand DM, Earp S, et al. (2021) Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577]. Pharmacology & Therapeutics. 107822 |
Lee-Sherick AB, Jacobsen KM, Henry CJ, et al. (2020) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5 |
Huelse J, Fridlyand D, Earp S, et al. (2020) MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics. 107577 |
Yan D, Huelse J, Parker R, et al. (2020) Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib Cancer Research. 80: 1882-1882 |